---
figid: PMC2745153__grsb-2008-163f2
figtitle: Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems
  Biology of Tumor Cell-Signaling
organisms:
- Bos taurus
- Canis lupus familiaris
- Ovis aries
- Mus musculus
- Rattus norvegicus
- Gallus gallus
- Xenopus laevis
- Homo sapiens
- Caenorhabditis elegans
organisms_ner:
- Bos taurus
- Mus musculus
- Gallus gallus
- Homo sapiens
- Rattus norvegicus
- Ovis aries
- Canis lupus familiaris
- Xenopus laevis
- Drosophila melanogaster
pmcid: PMC2745153
filename: grsb-2008-163f2.jpg
figlink: /pmc/articles/PMC2745153/figure/f2-grsb-2008-163/
number: F2
caption: 'HMG-R inhibitors block the conversion of 3-HMG-CoA to mevalonate, preventing
  the formation of Farnesyl-PP and Geranylgeranyl-PP and subsequently, prenylation
  of Ras, Raf, Rho and lamin B. HMG-R inhibitors also block cholesterol, thereby disrupting
  Cav-1 associated signaling and lipid bodies. COX-2 activates β-Catenin, AKT and
  subsequently STAT3 and NFκB. STAT3, β-Catenin and NFκB then translocate to the nucleus
  and transcribe genes involved in survival and proliferation. COX-2 also promotes
  lipid body formation.Abbreviations: NFκB: nuclear factor κB; Cyc D1: Cyclin D1;
  B-Cat: β-catenin; ERK: extracellular regulated kinase; AKT: also known as protein
  kinase B (PKB); STAT3: signal trandsducer and activator of transcription; Cav-1:
  caveolin-1; EGFR: epidermal growth factor receptor; IGFR: insulin growth factor
  receptor; TM: transmembrane protein; LB: lipid bodies; PL: phospho lipids; AA: arachidonic
  acid; COX-2: cyclooxygenase 2; VEGF: vascular endothelial growth factor; iNOS: inducible
  nitric oxide synthase; ilk: integrin linked kinase; ROCK: Rho kinase: MEK: MAP kinase.'
papertitle: Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems
  Biology of Tumor Cell-Signaling.
reftext: Suresh Guruswamy, et al. Gene Regul Syst Bio. 2008;2:163-176.
year: '2008'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9090747
figid_alias: PMC2745153__F2
figtype: Figure
redirect_from: /figures/PMC2745153__F2
ndex: fde988a4-df11-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2745153__grsb-2008-163f2.html
  '@type': Dataset
  description: 'HMG-R inhibitors block the conversion of 3-HMG-CoA to mevalonate,
    preventing the formation of Farnesyl-PP and Geranylgeranyl-PP and subsequently,
    prenylation of Ras, Raf, Rho and lamin B. HMG-R inhibitors also block cholesterol,
    thereby disrupting Cav-1 associated signaling and lipid bodies. COX-2 activates
    β-Catenin, AKT and subsequently STAT3 and NFκB. STAT3, β-Catenin and NFκB then
    translocate to the nucleus and transcribe genes involved in survival and proliferation.
    COX-2 also promotes lipid body formation.Abbreviations: NFκB: nuclear factor κB;
    Cyc D1: Cyclin D1; B-Cat: β-catenin; ERK: extracellular regulated kinase; AKT:
    also known as protein kinase B (PKB); STAT3: signal trandsducer and activator
    of transcription; Cav-1: caveolin-1; EGFR: epidermal growth factor receptor; IGFR:
    insulin growth factor receptor; TM: transmembrane protein; LB: lipid bodies; PL:
    phospho lipids; AA: arachidonic acid; COX-2: cyclooxygenase 2; VEGF: vascular
    endothelial growth factor; iNOS: inducible nitric oxide synthase; ilk: integrin
    linked kinase; ROCK: Rho kinase: MEK: MAP kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - RHO
  - ILK
  - NOS2
  - PL
  - COX2
  - AKT1
  - STAT3
  - VEGFA
  - tm
  - Egf
  - Rho
  - Rhod
  - Ea2
  - Ilk
  - Nos2
  - Nfkb1
  - pl
  - H2-Aa
  - Ptgs2
  - Mdk
  - Ephb2
  - Mapk1
  - Zhx2
  - Akt1
  - Stat3
  - ras
  - Hras
  - Kras
  - Rem1
  - Vegfa
  - Trp53
  - Ppia-ps1
  - Ccnd1
  - OPN1MSW
  - HMGCR
  - CYCS
  - LMNA
  - IGF1R
  - RHOD
  - RHOA
  - RHOB
  - RHOC
  - ISYNA1
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - ROCK1
  - ROCK2
  - PTGS2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT2
  - AKT3
  - HMGA1
  - KRAS
  - HRAS
  - NRAS
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - GNAS
  - GNAL
  - GNAQ
  - GNA11
  - GNA14
  - GNA15
  - GNA12
  - GNA13
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - TP53
  - TP63
  - TP73
  - Rela
  - Ephb1
  - Tp53
  - rho.L
  - rho.2.L
  - ilk.S
  - isyna1.S
  - isyna1.L
  - nfkb1.L
  - nfkb1.S
  - ptgs2.S
  - ptgs2.L
  - mapk1.L
  - mapk1.S
  - raf1.S
  - stat3.L
  - plin1.L
  - vegfa.L
  - vegfa.S
  - tp53.L
  - tp53.S
  - lmnb1.L
  - lmnb1.S
  - Egfr
  - fr
  - rho
  - Bx
  - Rho1
  - Lcp65Ab1
  - Inos
  - Nos
  - Dif
  - dl
  - Rel
  - Rok
  - arm
  - CG1673
  - aa
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Raf
  - Akt
  - Hmgcr
  - Ras64B
  - Ras85D
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - p53
  - betaTub60D
  - hth
  - Lam
  - cyc
  - CycE
  - Cyt-c-d
  - Cyt-c-p
  - cype
  - Cholesterol
  - Mevalonate
  - Prostaglandins
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
